Inhibiting breast cancer progression by exploiting TGFbeta signaling

Related Experiment Video

Updated: Jun 12, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Sarah E Baxley1, Rosa Serra

  • 1Department of Cell Biology, University of Alabama at Birmingham, 1918 University Blvd. 660 MCLM, Birmingham, AL 35294-0005, USA.

Current Drug Targets
|June 16, 2010
PubMed

Insights

Transforming Growth Factor beta (TGFbeta) signaling has a dual role in breast cancer, suppressing early tumors but promoting metastasis. Understanding TGFbeta pathways is crucial for developing new breast cancer therapeutics.

Area of Science:

  • Cellular Biology
  • Cancer Research
  • Molecular Signaling

Background:

  • Transforming Growth Factor beta (TGFbeta) signaling is vital for cellular functions, organ development, and tissue repair.
  • Aberrant TGFbeta signaling is linked to the development and progression of various cancers.
  • In breast cancer, TGFbeta exhibits a dual role: tumor-suppressive in early stages and tumor-promoting during metastasis.

Purpose of the Study:

  • To review the multifaceted role of TGFbeta in breast cancer progression.
  • To identify and discuss potential therapeutic targets within the TGFbeta pathway for breast cancer treatment.

Main Methods:

  • Literature review and synthesis of existing research on TGFbeta signaling in breast cancer.
  • Analysis of TGFbeta's dual function in different stages of breast cancer.
  • Identification of key molecular targets for therapeutic intervention.

Main Results:

  • TGFbeta signaling is critical in regulating cellular processes relevant to cancer.
  • The pathway's context-dependent activity (tumor-suppressive vs. tumor-promoting) is key to its role in breast cancer.
  • Specific components of the TGFbeta pathway represent viable targets for novel breast cancer therapies.

Conclusions:

  • Targeting TGFbeta signaling pathways holds promise for developing innovative breast cancer treatments.
  • Further research into TGFbeta's complex role can lead to improved therapeutic strategies to reduce breast cancer morbidity and mortality.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...